Lutetium (177Lu) oxodotreotide

Lutetium (¹⁷⁷Lu) dotatate
INN: lutetium (¹⁷⁷Lu) oxodotreotide
Clinical data
Trade names	Lutathera
AHFS/Drugs.com	Monograph
License data	US DailyMed: Lutathera;
Routes of; administration	Intravenous
Drug class	Radiolabeled somatostatin analog
ATC code	V10XX04 (WHO) ;
Legal status
Legal status	CA: Rx-only / Schedule C; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name (177Lu)lutetium(3+) 2-[4-({[(1R)-1-{[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-{[(1S,2R)-1-carboxy-2-hydroxypropyl]-C-hydroxycarbonimidoyl}-6,9,12,15,18-pentahydroxy-7-[(1R)-1-hydroxyethyl]-13-[(1H-indol-3-yl)methyl]-16-[(4-oxidophenyl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaen-19-yl]-C-hydroxycarbonimidoyl}-2-phenylethyl]-C-hydroxycarbonimidoyl}methyl)-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetate;
CAS Number	437608-50-9;
PubChem CID	71587735;
DrugBank	DB13985;
UNII	AE221IM3BB;
KEGG	D11033;
CompTox Dashboard (EPA)	DTXSID20195927 ;
Chemical and physical data
Formula	C65H87LuN14O19S2
Molar mass	1607.58 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)NC(C(C)O)C(=O)O)O.[Lu+3];
	InChI InChI=1S/C65H90N14O19S2.Lu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+3/p-3/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+2; Key:MXDPZUIOZWKRAA-PRDSJKGBSA-K;

Lutetium (¹⁷⁷Lu) oxodotreotide (INN) or ¹⁷⁷Lu dotatate, brand name Lutathera, is a chelated complex of a radioisotope of the element lutetium with dotatate, used in peptide receptor radionuclide therapy. Specifically, it is used in the treatment of cancers which express somatostatin receptors. It is a radiolabeled somatostatin analog.

Alternatives to ¹⁷⁷Lu-dotatate include yttrium-90 dotatate or DOTATOC. The longer range of the beta particles emitted by ⁹⁰Y, which deliver the therapeutic effect, may make it more suitable for large tumors with ¹⁷⁷Lu reserved for smaller volumes

The US Food and Drug Administration (FDA) considers ¹⁷⁷Lu dotatate to be a first-in-class medication.